Alwin Capital Alwin Capital Alwin Capital

Alwin Capital

Identifying life science breakthroughs to address unmet clinical needs, we invest in translational medicine frontiers to capture China opportunities.

Positioning

Alwin Capital is a leading venture capital in China specializing in early stage life science investments. Driven by theme-focused research in life science, Alwin Capital has developed investment strategies that capture outstanding opportunities for innovative diagnostic and therapeutic developments. We are committed to the long-term investment in life science with the pursuit of the excess investment return based on the scientific insights.

Founded in 2015, Alwin Capital was formed by former CICC senior executives, bringing in decades of experience in healthcare research and medical markets. Alwin Capital currently manage three venture funds with more than RMB 1 Billion in AUM, having invested in dozens of companies in life science and cultivated a bunch of leading companies in respective segments.

Portfolio

Over the past two decades, life science discoveries have been transformed into clinical applications and solutions, revealing a whole new horizon for healthcare industries. In the theme line based on gene sequencing, the industrial chain of molecular diagnosis has developed in an all-round way. In the theme line based on gene synthesis, drug research and development has entered the macromolecular platform from the small molecular platform, and then entered the living drug platform. In the theme line based on gene editing, new clinical technologies such as gene therapy have infiltrated the real clinical scenario. At the same time, life science, driven by artificial intelligence technology, has stepped a new development stage of digital life and precision medicine.

Under the current background of the development of life science and clinical medicine, adhering to the professional investment research in life science and the profound understanding of portfolio management, Alwin Capital has formed a systematic investment layout covering Innovative Drugs, Molecular Diagnostics, Innovative Hardware, Scientific Services and AI Applications.

  • RNA Drugs-Immorna

    Technology-leading mRNA drug discovery company with systematic layout in vaccines of infectious diseases

  • Gene Therapy-Hui-Gene

    Hui-Gene Therapeutics is an innovative gene therapy company based on both AAV platform and CRISPR technology.

  • Intestinal
    Microbiome-Xbiome

    Xbiome is the only microbiome drug R&D company in China with global leading progress and advancement.

  • Complement Drugs-Kira Pharm

    Kira Pharm is a global complement drug R&D company founded by a world leading scientist in the field of complement system.

  • ADC Drugs-Bliss-Bio

    Bliss-Bio focuses its pipeline on ADC drugs with a seasoned management team with impressive track records and execution capabilities.

  • Cell Therapy-Uni-CAR

    CAR-T cell therapy company with its first-in-class candidate of IL-6 knockdown CD19 CAR-T targeting CNS leukemia

  • O/I Drugs-Adlai Nortye

    Adlai Nortye is an onco-immunology drug R&D company with a strong immunotherapy tumor pipeline entering phase III clinical trials.

  • mRNA

    Leading mRNA therapeutics platform in China, systematic layout in the pipeline of tumor neoantigen vaccines, cytokines and etc.

  • Edigene

    Leading domestic gene editing company with its pipeline expected to be the first clinical-stage gene editing candidate in China

  • Cancer Liquid Biopsy-Genecast

    Genecast is the leading company in the field of tumor liquid biopsy in China, providing a full solution for tumor companion diagnosis

  • Mass Spectrometry Testing-Yingsheng Biology

    Yingsheng Biology is a leading player in mass spectrometry testing market with a pipeline covering key products in China.

  • Genetic Disease Testing-Chigene

    Chigene is the China market leader in genetic disease testing with the largest database of genetic disease patients.

  • Molecular Pathology Platform-Geneis:

    Geneis is a multi-platform molecular pathology service provider to hospitals with comprehensive capabilities.

  • DTC Gene Testing-23 MoFang

    23 MoFang is the No. 1 DTC gene testing player and accounts for 40% of market share in China.

  • Forensic DNA Testing-SuperBio

    SuperBio is the leader in forensic DNA testing with patented technologies and devices in China.

  • ONT Nanopore Sequencing-Qitan Tech

    Qitan Tech is an innovative hardware R&D company in the area of ONT nanopore sequencing with the most advanced progress in China.

  • Micro Droplet Platform-Sniper

    Sniper innovated its breakthrough micro droplet generation technology platform, realizing transformation in the field of digital PCR.

  • Gene Synthesis-Synbio Tech

    Synbio Tech is a high- throughput gene synthesis company with exploration of in de novo design and synthesis of antibodies.

  • The 3rd Generation Gene Sequencing-FraserGen

    Frasergen is offering advanced 3rd generation gene sequencing services to scientific research market.

  • FFR-CT AI Software-Keya Medical

    Keya Medical is an AI clinical diagnosis software development company. Its FFR-CT has been approved as the first AI Class III medical device by CFDA.

  • Radiotherapy AI Software-Datu Medical

    Datu Medical provides advanced radiotherapy software in China market. Its radiotherapy sketching software was first approved as the Class III medical device by CFDA.

  • Dental Invisible Correction-Click:

    Clickalign is an innovative company with overall layout of dental invisible orthodontics and digital dental service.

  • RNA Drugs-Immorna

    Technology-leading mRNA drug discovery company with systematic layout in vaccines of infectious diseases

  • Intestinal
    Microbiome-Xbiome

    Xbiome is the only microbiome drug R&D company in China with global leading progress and advancement.

  • Gene Therapy-Hui-Gene

    Hui-Gene Therapeutics is an innovative gene therapy company based on both AAV platform and CRISPR technology.

  • Complement Drugs-Kira Pharm

    Kira Pharm is a global complement drug R&D company founded by a world leading scientist in the field of complement system.

  • ADC Drugs-Bliss-Bio

    Bliss-Bio focuses its pipeline on ADC drugs with a seasoned management team with impressive track records and execution capabilities.

  • Cell Therapy-Uni-CAR

    CAR-T cell therapy company with its first-in-class candidate of IL-6 knockdown CD19 CAR-T targeting CNS leukemia

  • O/I Drugs-Adlai Nortye

    Adlai Nortye is an onco-immunology drug R&D company with a strong immunotherapy tumor pipeline entering phase III clinical trials.

  • mRNA

    Leading mRNA therapeutics platform in China, systematic layout in the pipeline of tumor neoantigen vaccines, cytokines and etc.

  • Edigene

    Leading domestic gene editing company with its pipeline expected to be the first clinical-stage gene editing candidate in China

  • Cancer Liquid Biopsy-Genecast

    Genecast is the leading company in the field of tumor liquid biopsy in China, providing a full solution for tumor companion diagnosis

  • Mass Spectrometry Testing-Yingsheng Biology

    Yingsheng Biology is a leading player in mass spectrometry testing market with a pipeline covering key products in China.

  • Genetic Disease Testing-Chigene

    Chigene is the China market leader in genetic disease testing with the largest database of genetic disease patients.

  • Molecular Pathology Platform-Geneis:

    Geneis is a multi-platform molecular pathology service provider to hospitals with comprehensive capabilities.

  • Forensic DNA Testing-SuperBio

    SuperBio is the leader in forensic DNA testing with patented technologies and devices in China.

  • DTC Gene Testing-23 MoFang

    23 MoFang is the No. 1 DTC gene testing player and accounts for 40% of market share in China.

  • ONT Nanopore Sequencing-Qitan Tech

    Qitan Tech is an innovative hardware R&D company in the area of ONT nanopore sequencing with the most advanced progress in China.

  • Micro Droplet Platform-Sniper

    Sniper innovated its breakthrough micro droplet generation technology platform, realizing transformation in the field of digital PCR.

  • Gene Synthesis-Synbio Tech

    Synbio Tech is a high- throughput gene synthesis company with exploration of in de novo design and synthesis of antibodies.

  • The 3rd Generation Gene Sequencing-FraserGen

    Frasergen is offering advanced 3rd generation gene sequencing services to scientific research market.

  • FFR-CT AI Software-Keya Medical

    Keya Medical is an AI clinical diagnosis software development company. Its FFR-CT has been approved as the first AI Class III medical device by CFDA.

  • Radiotherapy AI Software-Datu Medical

    Datu Medical provides advanced radiotherapy software in China market. Its radiotherapy sketching software was first approved as the Class III medical device by CFDA.

  • Dental Invisible Correction-Click:

    Clickalign is an innovative company with overall layout of dental invisible orthodontics and digital dental service.

Team

Alwin’s founding partners have been working together for nearly ten years, building a strong team culture and mutual trust over the course of their investment careers. They believe in science and the power of research. They all work in the front line to follow their beliefs and principles across their investment process. Strongly supported by a high-profile advisory board from the industry and capital market as well, Alwin is on track to explore and capture the investment opportunities in life science.

孙雅娜
Yana Sun Ph.D., CFA

Founding Partner
  • Medical Doctor from Peking Union Medical College
  • Managing Director with 13 years working experience at CICC
  • Was the top ranked healthcare equity analyst in China capital market
  • Was Head of Strategic Research and Head of Wealth Investment
  • Highly forward-looking judgment on industry and capital market

丁雅坤
Yakun Ding

M.S - PKU
Founding Partner
  • M.S. from Peking University, B.S. from Fudan University
  • Nearly 10 years of investment and research experience in cutting-edge technology industry
  • An influential new-generation investor in life science venture investment in China
  • Led the investment in quite a few leading biotech companies and served as board member
  • Investment horizon across primary and secondary markets, China and overseas

师惠京
Huijing Shi

M.S. from University of International Business and Economics
Founding Partner
  • M.S. from University of International Business and Economics
  • COO at CICC fund of hedge funds, managing over RMB 5 Billion across 10 funds
  • Strong capability in financial risk control and fund operation
  • Comprehensive network among top financial institutions in China

刘嘉运
Jiayun Liu

M.S. from Hong Kong University
Investment Director
  • MPH from Hong Kong University, B.S Med from Fudan University
  • Years of work experience in the field of medicine across primary and secondary markets
  • Accumulated rich research experience in the scientific theme lines with insights
  • Comprehensive and practical experience in investment execution

张义斌
Yibin Zhang

Investment Director
  • M.S. from Peking University, B.S. from Central University of Finance and Economics
  • Was the head of investment and financing department in a China's leading online medical service company
  • Previous working experience in the top investment bank in China
  • Skillful in the post-investment management with comprehensive network and resources in financial market

张连山
Lianshan Zhang Ph.D.

Senior Advisor
  • Senior Vice President, Chief Scientist at Hengrui Pharmaceutical
  • (the largest innovative pharmaceutical company in China)
  • Was Senior chemical director at Marcadia, USA
  • 10 years working experience in Eli Lilly
  • One of the leading people of new drug research and development in China

曾皓
Howard Zeng

Senior Advisor
  • Was Head of Corporate Development at BGI Genomics (the largest gene sequencing company in China)
  • 8 years working experience at Merrill Lynch Investment Banks
  • 4 years working experience in bioinformatics at Merck, US
  • Providing cross-border visions between US and China

邱劲
Jin Qiu Ph.D.

Senior Advisor
  • Ph.D. in Finance from McGill University
  • Chief Investment Officer at CICC
  • Was the Head of Equity Research at CICC
  • Holding extensive influence in China capital market with his senior background